<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16828">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02887820</url>
  </required_header>
  <id_info>
    <org_study_id>PRO16060542</org_study_id>
    <nct_id>NCT02887820</nct_id>
  </id_info>
  <brief_title>Evaluating the Use of Thromboelastography (TEG) in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)</brief_title>
  <official_title>A Pilot Study in Feasibility and Safety: Point of Care Testing With Thromboelastography (TEG) for Blood Product Transfusion in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study that seeks to evaluate the feasibility and safety of using a TEG
      algorithm in addition to traditional laboratory tests to guide transfusion and coagulation
      management of ECMO patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All adult patients requiring ECMO will be considered for the trial, with a target enrollment
      of 50 participants over a two-year period. For each enrolled participant, a TEG transfusion
      algorithm will be followed for patients exhibiting inadequate hemostasis in the operating
      room (Flowchart 1), and then a second TEG algorithm will be followed in the ICU when
      hemostasis is normal and heparin is introduced (Flowchart 2). In addition to determining the
      compliance and feasibility of following these TEG algorithms, clinical outcome data
      including transfusion rates, types of blood products transfused, estimated blood loss and
      thrombotic events will be collected for every enrolled patient until they are discontinued
      from ECMO. Statistical analysis of the primary, secondary and tertiary endpoints of this
      study will determine the likelihood of exploring future clinical trials involving TEG-driven
      coagulation and transfusion management of the ECMO population.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants whose blood management care follows a TEG algorithm 90% of the time</measure>
    <time_frame>From time patient is placed on ECMO to 30-days post ECMO initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants that require transfusion of blood products</measure>
    <time_frame>From the time patient is placed on ECMO to 30-days post ECMO initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that experience bleeding or thrombotic-related adverse events, including deep venous thrombosis or pulmonary embolus</measure>
    <time_frame>From the time patient is placed on ECMO to 30-days post ECMO initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that experience adverse events including limb/colonic ischemia, sepsis, pneumonia, acute kidney injury, in-hospital mortality</measure>
    <time_frame>From the time patient is placed on ECMO to 30-days post ECMO initiation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Heart Disease</condition>
  <condition>Lung Disease</condition>
  <arm_group>
    <arm_group_label>Pilot Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects enrolled in the trial will be in the pilot group. These subjects will have traditional laboratory coagulation and blood transfusion tests (baseline arterial blood gas (ABG), complete blood count (CBC), fibrinogen, platelet count, aPTT, PT, anti-Xa, ACT), as well as thromboelastograph (TEG). Pertinent TEG results will include: heparinase-kaolin TEG maximum amplitude (MA) in millimeters (mm), heparinase-kaolin TEG r-time in seconds, heparinase-kaolin TEG alpha angle in degrees, and TEG functional fibrinogen (FLEV) MA in mm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thromboelastograph</intervention_name>
    <description>A thromboelastograph flowchart will be followed in addition to traditional laboratory tests to manage blood transfusion and coagulation decisions</description>
    <arm_group_label>Pilot Arm</arm_group_label>
    <other_name>TEG 5000</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient's requiring ECMO placement

        Exclusion Criteria:

          -  Other than children less than 18 years of age, no one will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Esper, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy L Monroe, BS</last_name>
    <phone>412-609-6161</phone>
    <email>monroeal@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UPMC Presbyterian Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Oliver WC. Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth. 2009 Sep;13(3):154-75. doi: 10.1177/1089253209347384. Review.</citation>
    <PMID>19767408</PMID>
  </results_reference>
  <results_reference>
    <citation>Esmon CT. The impact of the inflammatory response on coagulation. Thromb Res. 2004;114(5-6):321-7. Review.</citation>
    <PMID>15507261</PMID>
  </results_reference>
  <results_reference>
    <citation>Muntean W. Coagulation and anticoagulation in extracorporeal membrane oxygenation. Artif Organs. 1999 Nov;23(11):979-83.</citation>
    <PMID>10564301</PMID>
  </results_reference>
  <results_reference>
    <citation>Colby CE, Sheehan A, Benitz W, Van Meurs K, Halamek LP, Moss RL. Maintaining adequate anticoagulation on extracorporeal membrane oxygenation therapy: Hemochron Junior Low Range versus Hemochron 400. J Extra Corpor Technol. 2003 Mar;35(1):35-8.</citation>
    <PMID>12680494</PMID>
  </results_reference>
  <results_reference>
    <citation>Reiner JS, Coyne KS, Lundergan CF, Ross AM. Bedside monitoring of heparin therapy: comparison of activated clotting time to activated partial thromboplastin time. Cathet Cardiovasc Diagn. 1994 May;32(1):49-52.</citation>
    <PMID>8039220</PMID>
  </results_reference>
  <results_reference>
    <citation>Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Spitznagel E, Cox JL, Lappas DG. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg. 1994 Dec;108(6):1076-82.</citation>
    <PMID>7983877</PMID>
  </results_reference>
  <results_reference>
    <citation>Afshari A, Wikkelsø A, Brok J, Møller AM, Wetterslev J. Thrombelastography (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD007871. doi: 10.1002/14651858.CD007871.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;8:CD007871.</citation>
    <PMID>21412912</PMID>
  </results_reference>
  <results_reference>
    <citation>Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg. 1999 Feb;88(2):312-9.</citation>
    <PMID>9972747</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 3, 2017</lastchanged_date>
  <firstreceived_date>August 25, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Stephen Esper</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesiology, Chief of Perioperative Services</investigator_title>
  </responsible_party>
  <keyword>ECMO</keyword>
  <keyword>TEG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
